Prevention of Venous Thromboembolism in 2020 and Beyond
Open accessThe DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Abstract
Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830 · cited 1×
“One important exception to this recommendation is the case of low-risk isolated subsegmental PE with normal ultrasonography of the legs, which should be managed with clinical surveillance over anticoagulation [36].”
BackgroundCRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., Merdji, H., Clere-Jehl, R., Schenck, M., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06062-x · Cited by 2,792 · cited 1×
“In a study of two French intensive care units that utilized systematic screening with compression ultrasound 1–3 days after admission, the proportion of patients with VTE was 69%, with 23% of patients diagnosed with pulmonary embolism despite prophylaxis, and in some cases despite therapeutic anticoagulation [149,150].”
BackgroundSilverstein, M. D., Heit, J. A., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.6.585 · Cited by 2,660 · cited 2×
“During childbearing years, the incidence of VTE increases in women, and in the third decade of life, the risk of first VTE events in women exceeds that in men [15,42].”
BackgroundCOVID-19 and its implications for thrombosis and anticoagulation
Connors, J. M., & Levy, J. H. (2020) · Blood · doi:10.1182/blood.2020006000 · Cited by 2,369 · cited 2×
“of evidence suggests that immunothrombosis contributes to in situ development of pulmonary artery thrombi [138,142,143].”
BackgroundDevelopment and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Case-Control Study
Heit, J. A., Silverstein, M. D., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.809 · Cited by 2,171
Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., Kucher, N., Studt, J.-D., Sacco, C., Bertuzzi, A., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.024 · Cited by 2,054 · cited 1×
“5%, and a rate of positive imaging tests of 46%, potentially indicating underdiagnosis in this population [144].”
BackgroundIncidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
Pengo, V., Lensing, A. W. A., Prins, M. H., Marchiori, A., Davidson, B. L., Tiozzo, F., Albanese, P., Biasiolo, A., Pegoraro, C., Iliceto, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032274 · Cited by 1,828 · cited 1×
“The prevalence of CTEPH after VTE varies significantly in the literature and is estimated at 3–4% [46,47].”
BackgroundPrevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia
Cui, S., Chen, S., Li, X., Liu, S., & Wang, F. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14830 · Cited by 1,806 · cited 2×
“The development of VTE in COVID-19 patients appears to correlate with more severe disease course, higher D-dimer, higher CRP, and mortality [142,146,151].”
BackgroundMethodAnderson, F. A. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400050081016 · Cited by 1,669 · cited 1×
“In clinical practice, about two-thirds of VTE episodes manifest as DVT and one-third as PE with or without DVT [2,3].”
BackgroundEdoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711948 · Cited by 1,633
Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D., Kant, K. M., Kaptein, F. H. J., van Paassen, J., Stals, M. A. M., Huisman, M. V., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.041 · Cited by 1,601 · cited 3×
“of evidence suggests that immunothrombosis contributes to in situ development of pulmonary artery thrombi [138,142,143].”
BackgroundSamama, M. M., Cohen, A. T., Darmon, J.-Y., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Nguyen, H., Olsson, C.-G., Turpie, A. G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411103 · Cited by 1,584 · cited 1×
“Anticoagulant prophylaxis to prevent VTE results in a 50–70% reduction in the rate of VTE [122,123].”
BackgroundAgnelli, G., Anderson, F., Arcelus, J., Bergqvist, D., Brecht, J., Greer, I., Heit, J., Hutchinson, J., Kakkar, A., Mottier, D., et al. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-03-0212 · Cited by 1,566 · cited 1×
“In one estimate, VTE related to hospitalizations accounted for 71% of all VTE related death [41].”
BackgroundFox, S. E., Akmatbekov, A., Harbert, J. L., Li, G., Quincy Brown, J., & Vander Heide, R. S. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30243-5 · Cited by 1,526 · cited 1×
“of evidence suggests that immunothrombosis contributes to in situ development of pulmonary artery thrombi [138,142,143].”
BackgroundGlobal Burden of Thrombosis: Epidemiologic Aspects
Wendelboe, A. M., & Raskob, G. E. (2016) · Circulation Research · doi:10.1161/circresaha.115.306841 · Cited by 1,507 · cited 2×
“In a survey of six developed nations, only 28% of respondents were aware of the symptoms of PE and only 19% were aware of the symptoms of DVT [1].”
BackgroundKey, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01461 · Cited by 1,504 · cited 2×
“Even in the presence of malignancy, where treatment of incidental and distal events is generally accepted practice, a lack of evidence precludes definitive recommendations for treatment of subsegmental PE [40].”
BackgroundMethodIncidence of venous thromboembolism in hospitalized patients with COVID‐19
Middeldorp, S., Coppens, M., van Haaps, T. F., Foppen, M., Vlaar, A. P., Müller, M. C. A., Bouman, C. C. S., Beenen, L. F. M., Kootte, R. S., Heijmans, J., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14888 · Cited by 1,447 · cited 4×
“8–17%) and 23% (95% CI 14–33%) at 7 days and 14 days, respectively [151].”
BackgroundInfluentialIncidence and mortality of venous thrombosis: a population‐based study
NÆSS, I. A., CHRISTIANSEN, S. C., ROMUNDSTAD, P., CANNEGIETER, S. C., ROSENDAAL, F. R., & HAMMERSTRØM, J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02450.x · Cited by 1,413 · cited 4×
“Up to 60% of all VTE events occur in those over 70 years of age [14].”
BackgroundInfluentialHeit, J. A., Mohr, D. N., Silverstein, M. D., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.761 · Cited by 1,352
Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8034 · Cited by 1,348
Panigada, M., Bottino, N., Tagliabue, P., Grasselli, G., Novembrino, C., Chantarangkul, V., Pesenti, A., Peyvandi, F., & Tripodi, A. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14850 · Cited by 1,315
Collins, R., Scrimgeour, A., Yusuf, S., & Peto, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805053181805 · Cited by 1,314
BARBAR, S., NOVENTA, F., ROSSETTO, V., FERRARI, A., BRANDOLIN, B., PERLATI, M., DE BON, E., TORMENE, D., PAGNAN, A., & PRANDONI, P. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04044.x · Cited by 1,240 · cited 1×
“These scoring systems take into account variables known to increase the risk of VTE including a prior history of VTE, immobility, malignancy, stroke, advanced age, body mass index, acute infection, and in the case of the IMPROVE-DD score, the use of a biomarker—D-dimer greater than 2 times the upper limit of normal—to…”
BackgroundHigh incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients
Llitjos, J., Leclerc, M., Chochois, C., Monsallier, J., Ramakers, M., Auvray, M., & Merouani, K. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14869 · Cited by 1,206 · cited 1×
“In a study of two French intensive care units that utilized systematic screening with compression ultrasound 1–3 days after admission, the proportion of patients with VTE was 69%, with 23% of patients diagnosed with pulmonary embolism despite prophylaxis, and in some cases despite therapeutic anticoagulation [149,150].”
BackgroundWorld distribution of factor V Leiden
Rees, D. C., Cox, M., & Clegg, J. B. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91803-5 · Cited by 1,156 · cited 1×
“The most common thrombophilia mutation in Caucasian populations is heterozygous factor V Leiden, occurring in approximately 5% of northern European descendants [61].”
BackgroundThe epidemiology of venous thromboembolism
Heit, J. A., Spencer, F. A., & White, R. H. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1311-6 · Cited by 1,093
Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence
Poissy, J., Goutay, J., Caplan, M., Parmentier, E., Duburcq, T., Lassalle, F., Jeanpierre, E., Rauch, A., Labreuche, J., Susen, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047430 · Cited by 1,071 · cited 1×
“5% in the group of patients with influenza [148].”
BackgroundApixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., Brenner, B., Torbicki, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915103 · Cited by 1,067
Natural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048 · cited 1×
“Isolated calf DVT is significantly less likely to cause PE, and in many cases, its clinical relevance is uncertain [29,30].”
BackgroundAndrew, M., David, M., Adams, M., Ali, K., Anderson, R., Barnard, D., Bernstein, M., Brisson, L., Cairney, B., & DeSai, D. (1994) · Blood · doi:10.1182/blood.v83.5.1251.1251 · Cited by 1,038
Leizorovicz, A., Cohen, A. T., Turpie, A. G. G., Olsson, C.-G., Vaitkus, P. T., & Goldhaber, S. Z. (2004) · Circulation · doi:10.1161/01.cir.0000138928.83266.24 · Cited by 955 · cited 1×
“Anticoagulant prophylaxis to prevent VTE results in a 50–70% reduction in the rate of VTE [122,123].”
BackgroundParanjpe, I., Fuster, V., Lala, A., Russak, A. J., Glicksberg, B. S., Levin, M. A., Charney, A. W., Narula, J., Fayad, Z. A., Bagiella, E., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.001 · Cited by 920 · cited 1×
“Nonetheless, with a rate of VTE > 20% in populations of severe COVID-19, many physicians are calling for increased doses of prophylactic anticoagulation or the empiric use of therapeutic dose anticoagulation [141,151,153,154].”
BackgroundThrombosis Risk Assessment as a Guide to Quality Patient Care
Caprini, J. A. (2005) · Disease-a-Month · doi:10.1016/j.disamonth.2005.02.003 · Cited by 909
NATURAL HISTORY OF POSTOPERATIVE DEEP-VEIN THROMBOSIS
Kakkar, V. V., Howe, C. T., Flanc, C., & Clarke, M. B. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90002-6 · Cited by 899 · cited 1×
“Isolated calf DVT is significantly less likely to cause PE, and in many cases, its clinical relevance is uncertain [29,30].”
BackgroundCushman, M., Tsai, A. W., White, R. H., Heckbert, S. R., Rosamond, W. D., Enright, P., & Folsom, A. R. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.01.018 · Cited by 868
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814468 · Cited by 852 · cited 1×
“046), but no cases of fatal bleeding were observed [171].”
BackgroundSchünemann, H. J., Cushman, M., Burnett, A. E., Kahn, S. R., Beyer-Westendorf, J., Spencer, F. A., Rezende, S. M., Zakai, N. A., Bauer, K. A., Dentali, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022954 · Cited by 819
Greer, I. A., & Nelson-Piercy, C. (2005) · Blood · doi:10.1182/blood-2005-02-0626 · Cited by 797 · cited 1×
“Low-molecular-weight heparin is preferable to unfractionated heparin for prophylaxis in pregnancy to decrease the risks of heparin-associated osteoporosis and heparin-induced thrombocytopenia [92].”
BackgroundPrediction of venous thromboembolism in cancer patients
Ay, C., Dunkler, D., Marosi, C., Chiriac, A.-L., Vormittag, R., Simanek, R., Quehenberger, P., Zielinski, C., & Pabinger, I. (2010) · Blood · doi:10.1182/blood-2010-02-270116 · Cited by 772
Jick, H., Jick, S. S., Myers, M. W., Vasilakis, C., & Gurewich, V (1995) · The Lancet · doi:10.1016/s0140-6736(95)91928-7 · Cited by 726 · cited 1×
“The progestin component of COCs also appears to affect the rate of VTE, with Levonorgestrel and other second-generation progestins having a lower overall VTE risk than formulations with third-generation progestins such as Gesodestrel or Gestodene (see Table 2) [77,80].”
BackgroundRivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Khorana, A. A., Soff, G. A., Kakkar, A. K., Vadhan-Raj, S., Riess, H., Wun, T., Streiff, M. B., Garcia, D. A., Liebman, H. A., Belani, C. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814630 · Cited by 719 · cited 1×
“265) with one fatal bleeding event observed in the rivaroxaban group [172].”
BackgroundIncidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
Samama, M.-M. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3415 · Cited by 695
Bates, S. M., Jaeschke, R., Stevens, S. M., Goodacre, S., Wells, P. S., Stevenson, M. D., Kearon, C., Schunemann, H. J., Crowther, M., Pauker, S. G., et al. (2012) · Chest · doi:10.1378/chest.11-2299 · Cited by 686 · cited 2×
“Because ruling out VTE often requires clinical evaluation, laboratory testing, and imaging studies, the true healthcare burden of VTE must consider these costs as well as the cost of over- and under-diagnosis [26].”
Backgroundvan Hylckama Vlieg, A., Helmerhorst, F. M., Vandenbroucke, J. P., Doggen, C. J. M., & Rosendaal, F. R. (2009) · BMJ · doi:10.1136/bmj.b2921 · Cited by 666
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Büller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P., & Weitz, J. I. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405760 · Cited by 630 · cited 1×
“Early studies with factor XI antisense oligonucleotides were successful in lowering factor XI levels and preventing VTE without significant effects on hemostasis and bleeding [181].”
BackgroundAnderson, D. R., Morgano, G. P., Bennett, C., Dentali, F., Francis, C. W., Garcia, D. A., Kahn, S. R., Rahman, M., Rajasekhar, A., Rogers, F. B., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000975 · Cited by 626
Bates, S. M., Rajasekhar, A., Middeldorp, S., McLintock, C., Rodger, M. A., James, A. H., Vazquez, S. R., Greer, I. A., Riva, J. J., Bhatt, M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024802 · Cited by 625
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Cohen, A. T., Spiro, T. E., Büller, H. R., Haskell, L., Hu, D., Hull, R., Mebazaa, A., Merli, G., Schellong, S., Spyropoulos, A. C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1111096 · Cited by 607 · cited 1×
“Recently, two studies examined the benefit of extending thromboprophylaxis with oral options but did not provide definite evidence of net clinical benefit [133,134].”
BackgroundHeit, J. A., Silverstein, M. D., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.5.445 · Cited by 594 · cited 1×
“virtually all of the overall case fatality for VTE, and the initial presentation for 24% of PE patients is sudden death [43].”
BackgroundApixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial
McBane, R. D., Wysokinski, W. E., Le‐Rademacher, J. G., Zemla, T., Ashrani, A., Tafur, A., Perepu, U., Anderson, D., Gundabolu, K., Kuzma, C., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14662 · Cited by 591 · cited 1×
“In those with cancer, patient-reported quality of life is better with oral anticoagulant treatment compared to daily subcutaneous LMWH injection [180].”
BackgroundCanonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569
Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis
Horsted, F., West, J., & Grainge, M. J. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001275 · Cited by 565
Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE
Spyropoulos, A. C., Anderson, F. A., FitzGerald, G., Decousus, H., Pini, M., Chong, B. H., Zotz, R. B., Bergmann, J.-F., Tapson, V., Froehlich, J. B., et al. (2011) · Chest · doi:10.1378/chest.10-1944 · Cited by 550 · cited 3×
“As in surgical populations, 45–57% of VTE related to medical hospitalization occur during the hospitalization itself [118,119].”
BackgroundGrosse, S. D., Nelson, R. E., Nyarko, K. A., Richardson, L. C., & Raskob, G. E. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2015.11.033 · Cited by 548 · cited 1×
“In the United States, this translates to 300,000–600,000 cases of VTE per year, and annual incident VTE events are estimated to cost US healthcare more than 7 billion dollars each year [17].”
BackgroundEnde-Verhaar, Y. M., Cannegieter, S. C., Vonk Noordegraaf, A., Delcroix, M., Pruszczyk, P., Mairuhu, A. T. A., Huisman, M. V., & Klok, F. A. (2017) · European Respiratory Journal · doi:10.1183/13993003.01792-2016 · Cited by 521 · cited 1×
“The prevalence of CTEPH after VTE varies significantly in the literature and is estimated at 3–4% [46,47].”
BackgroundInfection and inflammation and the coagulation system
Levi, M. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00857-x · Cited by 517
Tagalakis, V., Patenaude, V., Kahn, S. R., & Suissa, S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.02.024 · Cited by 463
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients
Cohen, A. T., Harrington, R. A., Goldhaber, S. Z., Hull, R. D., Wiens, B. L., Gold, A., Hernandez, A. F., & Gibson, C. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601747 · Cited by 441 · cited 1×
“Recently, two studies examined the benefit of extending thromboprophylaxis with oral options but did not provide definite evidence of net clinical benefit [133,134].”
BackgroundAspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty
Anderson, D. R., Dunbar, M., Murnaghan, J., Kahn, S. R., Gross, P., Forsythe, M., Pelet, S., Fisher, W., Belzile, E., Dolan, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712746 · Cited by 439 · cited 1×
“With current prophylaxis, early ambulation, and improved operative techniques, rates of thrombosis may be decreasing further [109].”
BackgroundZhang, L., Feng, X., Zhang, D., Jiang, C., Mei, H., Wang, J., Zhang, C., Li, H., Xia, X., Kong, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046702 · Cited by 439 · cited 1×
“0 μg/mL and a Padua prediction score ≥ 4 may be useful markers for predicting DVT in hospitalized COVID-19 patients and require further study [152].”
MethodVinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2019) · BMJ · doi:10.1136/bmj.k4810 · Cited by 433
Sweetland, S., Green, J., Liu, B., Berrington de Gonzalez, A., Canonico, M., Reeves, G., Beral, V., & collaborators, O. B. O. T. M. W. S. (2009) · BMJ · doi:10.1136/bmj.b4583 · Cited by 421
Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection
Wright, F. L., Vogler, T. O., Moore, E. E., Moore, H. B., Wohlauer, M. V., Urban, S., Nydam, T. L., Moore, P. K., & McIntyre, R. C. (2020) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2020.05.007 · Cited by 418
Clinical assessment of venous thromboembolic risk in surgical patients.
Caprini, J. A., Arcelus, J. I., Hasty, J. H., Tamhane, A. C., & Fabrega, F. (1991) · PubMed · Cited by 413
Risk Factors for Venous Thromboembolism: Results From the Copenhagen City Heart Study
Holst, A. G., Jensen, G., & Prescott, E. (2010) · Circulation · doi:10.1161/circulationaha.109.921460 · Cited by 396 · cited 1×
“Rates of VTE are lowest in Asian populations and highest in Northern European populations [18,19].”
BackgroundPregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism
van der Pol, L. M., Tromeur, C., Bistervels, I. M., Ni Ainle, F., van Bemmel, T., Bertoletti, L., Couturaud, F., van Dooren, Y. P. A., Elias, A., Faber, L. M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813865 · Cited by 359
Demelo-Rodríguez, P., Cervilla-Muñoz, E., Ordieres-Ortega, L., Parra-Virto, A., Toledano-Macías, M., Toledo-Samaniego, N., García-García, A., García-Fernández-Bravo, I., Ji, Z., de-Miguel-Diez, J., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.05.018 · Cited by 352 · cited 1×
“7% of patients, but nearly all of these asymptomatic events were distal DVT [145].”
BackgroundHansson, P.-O. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440360079008 · Cited by 346
Prevalence of Protein C Deficiency in the Healthy Population
Tait, R. C., Walker, I. D., Reitsma, P. H., Islam, S. I. A. M., McCall, F., Poort, S. R., Conkie, J. A., & Bertina, R. M. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1653730 · Cited by 336 · cited 1×
“Deficiencies of protein C and S are found in <1% of asymptomatic individuals [63,64].”
BackgroundPabinger, I., van Es, N., Heinze, G., Posch, F., Riedl, J., Reitter, E.-M., Di Nisio, M., Cesarman-Maus, G., Kraaijpoel, N., Zielinski, C. C., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30063-2 · Cited by 335 · cited 1×
“Attempts to further refine the Khorana score include the Cancer-And-Thrombosis-Study (CATS) score, which combines tumor subtype and D-dimer levels to predict those at greatest risk of cancer-associated thrombosis [178].”
MethodOral contraceptives and venous thromboembolism: a five-year national case-control study☆
Lidegaard, Ø., Edström, B., & Kreiner, S. (2002) · Contraception · doi:10.1016/s0010-7824(01)00307-9 · Cited by 334 · cited 7×
“One option for VTE prophylaxis in patients who choose to continue COCs or hormone replacement therapy after a first VTE event is to maintain anticoagulation therapy throughout the period of exogenous estrogen exposure.”
BackgroundInfluentialVenous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., & Lokkegaard, E. (2012) · BMJ · doi:10.1136/bmj.e2990 · Cited by 326
Januel, J.-M., Chen, G., Ruffieux, C., Quan, H., Douketis, J. D., Crowther, M. A., Colin, C., Ghali, W. A., Burnand, B., & IMECCHI Group, F. T. (2012) · JAMA · doi:10.1001/jama.2011.2029 · Cited by 311
Ray, J. G., & Chan, W. S. (1999) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199904000-00023 · Cited by 310 · cited 1×
“DVTs in the left leg greatly outnumber DVTs in the right leg during pregnancy [91].”
BackgroundMauracher, L. ‐., Posch, F., Martinod, K., Grilz, E., Däullary, T., Hell, L., Brostjan, C., Zielinski, C., Ay, C., Wagner, D. D., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13951 · Cited by 303
Risk of Recurrent Venous Thromboembolism in Patients With Common Thrombophilia: A Systematic Review
Ho, W. K., Hankey, G. J., Quinlan, D. J., & Eikelboom, J. W. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.729 · Cited by 302 · cited 1×
“The duration of anticoagulation therapy for patients with VTE should be determined on clinical grounds with attention paid to the circumstances and provoking factors of the inciting event rather than underlying genetic factors [70,71].”
BackgroundZhou, H., Murin, S., Harvey, D., & White, R. H. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-08-0506 · Cited by 295 · cited 1×
“A greater proportion of VTE events in Caucasian populations are idiopathic compared to Asian, African, and Hispanic populations [20].”
BackgroundProgestin-only contraception and thromboembolism: A systematic review
Tepper, N. K., Whiteman, M. K., Marchbanks, P. A., James, A. H., & Curtis, K. M. (2016) · Contraception · doi:10.1016/j.contraception.2016.04.014 · Cited by 272 · cited 1×
“Options for contraception after estrogen-associated VTE that do not increase the risk of VTE include barrier methods, progestin-only contraceptive pills, and both copper and progesterone-based intra-uterine devices [88,89].”
BackgroundVenous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis
Minet, C., Potton, L., Bonadona, A., Hamidfar-Roy, R., Somohano, C. A., Lugosi, M., Cartier, J.-C., Ferretti, G., Schwebel, C., & Timsit, J.-F. (2015) · Critical Care · doi:10.1186/s13054-015-1003-9 · Cited by 270 · cited 1×
“During ICU admissions, the need for prolonged immobilization, indwelling central venous catheters, and hypoxia due to acute respiratory distress syndrome are additional risk factors for development of thrombosis, which in part explains the high rate of VTE seen in patients with severe COVID-19 infection [137].”
BackgroundCowley, L. E., Farewell, D. M., Maguire, S., & Kemp, A. M. (2019) · Diagnostic and Prognostic Research · doi:10.1186/s41512-019-0060-y · Cited by 263 · cited 1×
“The development and validation of prediction models should seek to increase the accuracy of prediction without sacrificing usability [185,186].”
MethodSegal, J. B., Brotman, D. J., Necochea, A. J., Emadi, A., Samal, L., Wilson, L. M., Crim, M. T., & Bass, E. B. (2009) · JAMA · doi:10.1001/jama.2009.853 · Cited by 251
Seng, S., Liu, Z., Chiu, S. K., Proverbs-Singh, T., Sonpavde, G., Choueiri, T. K., Tsao, C.-K., Yu, M., Hahn, N. M., Oh, W. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4358 · Cited by 246 · cited 1×
“Gemcitabine and Cisplatin chemotherapy are strongly associated with VTE risk [156,157].”
BackgroundC. Dykes, A., Walker, I. D., McMahon, A. D., Islam, S. I. A. M., & Tait, R. C. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02813.x · Cited by 240 · cited 1×
“Deficiencies of protein C and S are found in <1% of asymptomatic individuals [63,64].”
BackgroundPrevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis
Dentali, F., Ageno, W., Becattini, C., Galli, L., Gianni, M., Riva, N., Imberti, D., Squizzato, A., Venco, A., & Agnelli, G. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.03.016 · Cited by 218 · cited 1×
“Asymptomatic or incidental PE is detected in approximately 1% of chest CT scans undertaken for indications other than PE [35].”
BackgroundJohnson, S. A., Stevens, S. M., Woller, S. C., Lake, E., Donadini, M., Cheng, J., Labarère, J., & Douketis, J. D. (2010) · JAMA · doi:10.1001/jama.2010.43 · Cited by 215 · cited 1×
“Less invasive studies, such as venous ultrasonography, are less sensitive in asymptomatic patients than in symptomatic patients [51,52].”
BackgroundSimone, B., De Stefano, V., Leoncini, E., Zacho, J., Martinelli, I., Emmerich, J., Rossi, E., Folsom, A. R., Almawi, W. Y., Scarabin, P. Y., et al. (2013) · European Journal of Epidemiology · doi:10.1007/s10654-013-9825-8 · Cited by 207
Clinical features and outcome of pulmonary embolism in children
Biss, T. T., Brandão, L. R., Kahr, W. H., Chan, A. K., & Williams, S. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07243.x · Cited by 207 · cited 1×
“The incidence of PE is lower in children, but when it is diagnosed, mortality remains substantial at 8–10% [54,55].”
BackgroundKAHN, S. R., KEARON, C., JULIAN, J. A., MACKINNON, B., KOVACS, M. J., WELLS, P., CROWTHER, M. A., ANDERSON, D. R., VAN NGUYEN, P., DEMERS, C., et al. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01216.x · Cited by 203 · cited 3×
“Three conditions that can develop despite appropriate treatment of VTE are post-thrombotic syndrome (PTS), chronic thromboembolic pulmonary hypertension (CTEPH), and post-PE syndrome.”
BackgroundInfluentialSelf-citationGohil, R., Peck, G., & Sharma, P. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-01-0013 · Cited by 196
Kruip, M. J. H. A., Slob, M. J., Schijen, J. H. E. M., van der Heul, C., & Büller, H. R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1631 · Cited by 194 · cited 1×
“In the general population, only one out of every five patients who are evaluated for VTE in the emergency department for VTE is diagnosed with VTE [23,24].”
BackgroundIncidence of Venous Thromboembolism in Asian Populations: A Systematic Review
Lee, L., Gallus, A., Jindal, R., Wang, C., & Wu, C.-C. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-02-0134 · Cited by 187 · cited 1×
“Rates of VTE are lowest in Asian populations and highest in Northern European populations [18,19].”
BackgroundObi, A. T., Pannucci, C. J., Nackashi, A., Abdullah, N., Alvarez, R., Bahl, V., Wakefield, T. W., & Henke, P. K. (2015) · JAMA Surgery · doi:10.1001/jamasurg.2015.1841 · Cited by 186
Cannegieter, S. C., Doggen, C. J. M., van Houwelingen, H. C., & Rosendaal, F. R. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030307 · Cited by 184
Rosenberg, D., Eichorn, A. M., Alarcon, M., McCullagh, L., McGinn, T. G., & Spyropoulos, A. C. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001152 · Cited by 183
Thomas, W., Varley, J., Johnston, A., Symington, E., Robinson, M., Sheares, K., Lavinio, A., & Besser, M. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.028 · Cited by 178 · cited 1×
“Nonetheless, with a rate of VTE > 20% in populations of severe COVID-19, many physicians are calling for increased doses of prophylactic anticoagulation or the empiric use of therapeutic dose anticoagulation [141,151,153,154].”
BackgroundDoes thrombophilia testing help in the clinical management of patients?
Middeldorp, S., & Van Hylckama Vlieg, A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07339.x · Cited by 177
Henke, P. K., Kahn, S. R., Pannucci, C. J., Secemksy, E. A., Evans, N. S., Khorana, A. A., Creager, M. A., Pradhan, A. D., & On behalf of the American Heart Association Advocacy Coordinating Committee (2020) · Circulation · doi:10.1161/cir.0000000000000769 · Cited by 176 · cited 2×
“A recent policy statement from the American Heart Association discusses the benefits of these interventions and provides recommendations for improving VTE prevention in hospitalized patients [132].”
Backgroundvan Hylckama Vlieg, A., Helmerhorst, F. M., & Rosendaal, F. R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.211482 · Cited by 175
Maatman, T. K., Jalali, F., Feizpour, C., Douglas, A., McGuire, S. P., Kinnaman, G., Hartwell, J. L., Maatman, B. T., Kreutz, R. P., Kapoor, R., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004466 · Cited by 174 · cited 1×
“Nonetheless, with a rate of VTE > 20% in populations of severe COVID-19, many physicians are calling for increased doses of prophylactic anticoagulation or the empiric use of therapeutic dose anticoagulation [141,151,153,154].”
BackgroundKourlaba, G., Relakis, J., Kontodimas, S., Holm, M. V., & Maniadakis, N. (2016) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2015.06.054 · Cited by 174
Late outcomes of pulmonary embolism: The post-PE syndrome
Sista, A. K., & Klok, F. A. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2017.06.017 · Cited by 160 · cited 1×
“Post-PE syndrome encompasses several long-term functional deficits that can occur after acute PE and are associated with a reduced health-related quality of life [49,50].”
BackgroundGibson, C. M., Spyropoulos, A. C., Cohen, A. T., Hull, R. D., Goldhaber, S. Z., Yusen, R. D., Hernandez, A. F., Korjian, S., Daaboul, Y., Gold, A., et al. (2017) · TH Open · doi:10.1055/s-0037-1603929 · Cited by 159
Spyropoulos, A. C., Lipardi, C., Xu, J., Peluso, C., Spiro, T. E., Sanctis, Y. D., Barnathan, E. S., & Raskob, G. E. (2020) · TH Open · doi:10.1055/s-0040-1705137 · Cited by 154
[Genetics of venous thromboembolism].
Alhenc‐Gelas, M., & Aiach, M. (2003) · PubMed · Cited by 152
Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients
Amin, A., Varker, H., Princic, N., Lin, J., Thompson, S., & Johnston, S. S. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.1002 · Cited by 152 · cited 2×
“As in surgical populations, 45–57% of VTE related to medical hospitalization occur during the hospitalization itself [118,119].”
BackgroundWalker, R. F., Zakai, N. A., MacLehose, R. F., Cowan, L. T., Adam, T. J., Alonso, A., & Lutsey, P. L. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.5135 · Cited by 150 · cited 1×
“Testosterone supplementation may increase the risk of venous thromboembolic disease, and ongoing use is correlated with increased VTE across a wide age range and without respect to endogenous testosterone levels [86].”
BackgroundHaut, E. R., Lau, B. D., Kraenzlin, F. S., Hobson, D. B., Kraus, P. S., Carolan, H. T., Haider, A. H., Holzmueller, C. G., Efron, D. T., Pronovost, P. J., et al. (2012) · Archives of Surgery · doi:10.1001/archsurg.2012.2024 · Cited by 147 · cited 1×
“Computer alert interventions and other systemic measures to ensure appropriate VTE assessment are effective at optimizing the implementation of VTE prophylaxis and reducing preventable VTE [130,131].”
BackgroundSultan, A. A., West, J., Grainge, M. J., Riley, R. D., Tata, L. J., Stephansson, O., Fleming, K. M., Nelson‐Piercy, C., & Ludvigsson, J. F. (2016) · BMJ · doi:10.1136/bmj.i6253 · Cited by 145 · cited 1×
“In cases where the benefits of pharmacologic prophylaxis are not clear, additional risk factors that could be considered include maternal age > 35, BMI > 30 kg/m2, twin pregnancy, and immobility as included in the Lyon VTE score [100], or stillbirth, pre-term birth, prolonged labor, infection, hemorrhage, and blood tr…”
BackgroundDarzi, A., Karam, S. G., Charide, R., Etxeandia‐Ikobaltzeta, I., Cushman, M., Gould, M. K., Mbuagbaw, L. C. E., Spencer, F. A., Spyropoulos, A. C., Streiff, M. B., et al. (2020) · Blood · doi:10.1182/blood.2019003603 · Cited by 139 · cited 1×
“Older age, elevated CRP, D-dimer, fibrinogen levels, heart rate, thrombocytosis, leukocytosis, fever, leg edema, immobility, paresis, previous history of VTE, thrombophilia, malignancy, critical illness, and infections are all risk factors for the development of VTE in hospitalized patients [120].”
BackgroundMansfield, A. S., Tafur, A. J., Wang, C. E., Kourelis, T., Wysokinska, E. M., & Yang, P. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13378 · Cited by 135
Lijfering, W. M., Middeldorp, S., Veeger, N. J. G. M., Hamulyák, K., Prins, M. H., Buller, H. R., & van der Meer, J. (2010) · Circulation · doi:10.1161/circulationaha.109.906347 · Cited by 129
Gerhardt, A., Scharf, R. E., Greer, I. A., & Zotz, R. B. (2016) · Blood · doi:10.1182/blood-2016-03-703728 · Cited by 122 · cited 1×
“6% across the antepartum and postpartum period [95,96].”
BackgroundFrère, C., Bournet, B., Gourgou, S., Fraisse, J., Canivet, C., Connors, J. M., Buscail, L., Farge, D., Bournet, B., Canivet, C., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.12.009 · Cited by 104 · cited 1×
“For pancreatic ductal adenocarcinoma, the incidence of VTE approaches 20% over the first twelve months after diagnosis, and this number may be even higher in populations with higher proportions of metastatic disease [159,160].”
BackgroundOedingen, C., Scholz, S. M., & Razum, O. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.03.005 · Cited by 103 · cited 7×
“One option for VTE prophylaxis in patients who choose to continue COCs or hormone replacement therapy after a first VTE event is to maintain anticoagulation therapy throughout the period of exogenous estrogen exposure.”
BackgroundInfluentialVenous thromboembolism as a cause of severe maternal morbidity and mortality in the United States
Abe, K., Kuklina, E. V., Hooper, W. C., & Callaghan, W. M. (2019) · Seminars in Perinatology · doi:10.1053/j.semperi.2019.03.004 · Cited by 101 · cited 2×
“The risk of thrombosis peaks at 1–3 weeks postpartum and remains elevated until up to 12 weeks postpartum [90].”
BackgroundTrousseau’s syndrome – what is the evidence?
Bergqvist, D., Wåhlander, K., Eriksson, H., Sternby, N. H., & Ögren, M. (2006) · Thrombosis and Haemostasis · doi:10.1160/th05-10-0694 · Cited by 99 · cited 1×
“On autopsy, more than 40% of pancreatic cancer patients are affected by VTE [161].”
BackgroundThrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening
Tavazzi, G., Civardi, L., Caneva, L., Mongodi, S., & Mojoli, F. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06040-3 · Cited by 95 · cited 1×
“An ICU series in Italy reported 22% of patients developed VTE [147].”
BackgroundMari, D., Ogliari, G., Castaldi, D., Vitale, G., Bollini, E. M., & Lio, D. (2008) · Immunity & Ageing · doi:10.1186/1742-4933-5-12 · Cited by 90
Anticoagulant treatment for subsegmental pulmonary embolism
Yoo, H. H. B., Queluz, T. H., & Dib, R. E. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010222.pub3 · Cited by 87
Fibrinogen, red blood cells, and factor XIII in venous thrombosis
Walton, B. L., Byrnes, J. R., & Wolberg, A. S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12918 · Cited by 87
Risk of Venous Thrombosis in Antithrombin Deficiency: A Systematic Review and Bayesian Meta-analysis
Borjas-Howard, J., Nasserinejad, K., Leebeek, F., Meijer, K., & Croles, F. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1625983 · Cited by 81 · cited 1×
“0) and increases the absolute risk of a first VTE to >1% per year [65].”
BackgroundVardi, M., Ghanem‐Zoubi, N., Zidan, R. A., Yurin, V., & Bitterman, H. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12108 · Cited by 80
Patell, R. D., Rybicki, L. A., McCrae, K. R., & Khorana, A. A. (2017) · American Journal of Hematology · doi:10.1002/ajh.24700 · Cited by 77
HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study
Rasmussen, L. D., Dybdal, M., Gerstoft, J., Kronborg, G., Larsen, C. S., Pedersen, C. D., Pedersen, G. F., Jensen, J., Pedersen, L. H., Sørensen, H. T., et al. (2010) · HIV Medicine · doi:10.1111/j.1468-1293.2010.00869.x · Cited by 76 · cited 1×
“In one study from South Africa, HIV was the most common identifiable risk factor for VTE, and yet in many studies of VTE, data on HIV are not reported [21,22].”
BackgroundRisk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study
Albertsen, I. E., Nielsen, P. B., Søgaard, M., Goldhaber, S. Z., Overvad, T. F., Rasmussen, L. H., & Larsen, T. B. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.04.042 · Cited by 72 · cited 1×
“The development and validation of prediction models should seek to increase the accuracy of prediction without sacrificing usability [185,186].”
MethodKline, J. A., Richardson, D. M., Than, M. P., Penaloza, A., & Roy, P. (2014) · Academic Emergency Medicine · doi:10.1111/acem.12471 · Cited by 71 · cited 2×
“In the general population, only one out of every five patients who are evaluated for VTE in the emergency department for VTE is diagnosed with VTE [23,24].”
BackgroundFamilial Clustering of High Factor VIII Levels in Patients With Venous Thromboembolism
Schambeck, C. M., Hinney, K., Haubitz, I., Taleghani, B. M., Wahler, D., & Keller, F. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.2.289 · Cited by 69
Machine learning to predict venous thrombosis in acutely ill medical patients
Nafee, T., Gibson, C. M., Travis, R. S., Yee, M. K., Kernéis, M., Chi, G., Alkhalfan, F., Hernandez, A. F., Hull, R. D., Cohen, A. T., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12292 · Cited by 68
Management of inherited thrombophilia: guide for genetics professionals
Varga, E., & Kujovich, J. L. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01746.x · Cited by 64 · cited 1×
“In asymptomatic patients with heterozygous factor V Leiden, heterozygous prothrombin gene mutation, protein C deficiency, and protein S deficiency, the absolute risk of VTE each year is approximately equal to the yearly risk of major bleeding on anticoagulation, and prophylaxis is not recommended for routine use when…”
BackgroundBouras, G., Burns, E. M., Howell, A.-M., Bottle, A., Athanasiou, T., & Darzi, A. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145759 · Cited by 63 · cited 1×
“Only 35% of post-operative VTE occurs while patients are still in hospital, and measures to prevent thrombosis must include preventative treatments prescribed in the outpatient setting [108].”
BackgroundVariations in incidence of venous thromboembolism in low-, middle-, and high-income countries
Siegal, D. M., Eikelboom, J. W., Lee, S. F., Rangarajan, S., Bosch, J., Zhu, J., & Yusuf, S. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa044 · Cited by 61 · cited 1×
“The incidence of VTE is higher in high-income countries than low-income countries, even after adjusting for age, ethnicity, incident cancer diagnoses, body mass index (BMI), and anti-thrombotic therapies [11].”
BackgroundSaragas, N. P., Ferrao, P. N. F., Saragas, E., & Jacobson, B. F. (2013) · Foot and Ankle Surgery · doi:10.1016/j.fas.2013.11.002 · Cited by 59
Ghanima, W., Wik, H. S., Tavoly, M., Enden, T. R., & Jelsness‐Jørgensen, L. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.07.025 · Cited by 57 · cited 1×
“Post-PE syndrome encompasses several long-term functional deficits that can occur after acute PE and are associated with a reduced health-related quality of life [49,50].”
BackgroundRupa‐Matysek, J., Lembicz, M., Rogowska, E. K., Gil, L., Komarnicki, M. A., & Batura‐Gabryel, H. (2018) · Medical Oncology · doi:10.1007/s12032-018-1120-9 · Cited by 56 · cited 1×
“Gemcitabine and Cisplatin chemotherapy are strongly associated with VTE risk [156,157].”
BackgroundA case–control study of seated immobility at work as a risk factor for venous thromboembolism
West, J., Perrin, K., Aldington, S., Weatherall, M., & Beasley, R. W. (2008) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2008.070366 · Cited by 51
Anticoagulant treatment for subsegmental pulmonary embolism
Yoo, H. H. B., Nogueira, V. D. S. N., & Bôas, P. J. F. V. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010222.pub4 · Cited by 50
Pedersen, A. B., Ehrenstein, V., Szépligeti, S. K., & Sørensen, H. T. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4213-y · Cited by 48 · cited 1×
“83% within 31–365 days after hip fracture surgery [105].”
BackgroundThrombosis Prophylaxis and Mortality Risk Among Critically Ill Adults
Lilly, C. M., Liu, X., Badawi, O., Franey, C. S., & Zuckerman, I. H. (2014) · CHEST Journal · doi:10.1378/chest.13-2160 · Cited by 46 · cited 2×
“In one large registry in the US, the use of pharmacologic VTE prophylaxis was associated with improved mortality in critically ill patients compared to no prophylaxis or mechanical VTE prophylaxis alone [6].”
BackgroundDargaud, Y., Rugeri, L., Fleury, C., Battie, C., Gaucherand, P., Huissoud, C., Rudigoz, R. C., Desmurs‐Clavel, H., Ninet, J., & Trzeciak, M. C. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13660 · Cited by 44 · cited 1×
“In cases where the benefits of pharmacologic prophylaxis are not clear, additional risk factors that could be considered include maternal age > 35, BMI > 30 kg/m2, twin pregnancy, and immobility as included in the Lyon VTE score [100], or stillbirth, pre-term birth, prolonged labor, infection, hemorrhage, and blood tr…”
BackgroundAbbattista, M., Gianniello, F., Novembrino, C., Clerici, M., Artoni, A., Bucciarelli, P., Capecchi, M., Peyvandi, F., & Martinelli, I. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30007-7 · Cited by 43 · cited 2×
“8) of patients experiencing a VTE event [95].”
BackgroundChan, N., Siegal, D. M., Lauw, M. N., Ginsberg, J. S., Eikelboom, J. W., Guyatt, G. H., & Hirsh, J. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1153-7 · Cited by 43 · cited 2×
“Recent thinking questions this assumption [32,52].”
BackgroundSelf-citationLi, A., Carlson, J. J., Kuderer, N. M., Schaefer, J. K., Li, S., Garcia, D. A., Khorana, A. A., Carrier, M., & Lyman, G. H. (2020) · Cancer · doi:10.1002/cncr.32724 · Cited by 42
Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study
Moigne, E. L., Tromeur, C., Delluc, A., Gouillou, M., Alavi, Z., Lacut, K., Mottier, D., & Gal, G. L. (2015) · Haematologica · doi:10.3324/haematol.2015.134882 · Cited by 41
Chauleur, C., Quenet, S., Varlet, M.-N., SEFFERT, P., Laporte, S., Decousus, H., & Mismetti, P. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2007.12.020 · Cited by 40
Post-thrombotic syndrome: Short and long-term incidence and risk factors
Ende-Verhaar, Y. M., Tick, L. W., Klok, F. A., Huisman, M. V., Rosendaal, F. R., le Cessie, S., & Cannegieter, S. C. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.03.003 · Cited by 40 · cited 3×
“Three conditions that can develop despite appropriate treatment of VTE are post-thrombotic syndrome (PTS), chronic thromboembolic pulmonary hypertension (CTEPH), and post-PE syndrome.”
BackgroundInfluentialDepietri, L., Marietta, M., Scarlini, S., Marcacci, M., Corradini, E., Pietrangelo, A., & Ventura, P. (2018) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1808-z · Cited by 40
Wang, Y.-Y.-Q., Attar, B. M., Fuentes, H. E., Yu, J., Zhang, H., & Tafur, A. J. (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617699088 · Cited by 38
The “Pregnancy Health-care Program” for the prevention of venous thromboembolism in pregnancy
Testa, S., Passamonti, S. M., Paoletti, O., Bucciarelli, P., Ronca, E., Riccardi, A., Rigolli, A., Zimmermann, A., & Martinelli, I. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1111-6 · Cited by 35
Global prevalence of prothrombin gene mutation G20210A and implications in women's health
Dziadosz, M., & Baxi, L. (2016) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000562 · Cited by 32 · cited 1×
“7% of asymptomatic individuals and demonstrates significant variation by region [62].”
BackgroundBaratloo, A., Safari, S., Rouhipour, A., Hashemi, B., Rahmati, F., Motamedi, M., Forouzanfar, M., & Haroutunian, P. (2014) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v2i1.14 · Cited by 30
Clinical Prognosis of Nonmassive Central and Noncentral Pulmonary Embolism
Gouin, B., Blondon, M., Jiménez, D., Fernández‐Capitán, C., Bounameaux, H., Soler, S., Duce, R., Sahuquillo, J. C., Ruiz‐Giménez, N., & Monréal, M. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.10.056 · Cited by 30 · cited 1×
“In contrast to pediatric patients, no significant provoking factor is identified in up to 45–50% of cases of new VTE in adults [14,56].”
BackgroundValerio, L., Ambaglio, C., Barone, M., Ciola, M., Konstantinides, S., Mahmoudpour, S. H., Picchi, C., Pieresca, C., Trinchero, A., & Barco, S. (2019) · TH Open · doi:10.1055/s-0039-1683374 · Cited by 30
Refaei, M., Xing, L., Lim, W., Crowther, M. A., & Boonyawat, K. (2017) · Case Reports in Hematology · doi:10.1155/2017/9261351 · Cited by 30 · cited 1×
“The patients in that study did not receive antithrombin substitution, and expert consultation with consideration for antithrombin concentrates has been suggested in high-risk patients to further reduce the risk of VTE [97,98].”
BackgroundCerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions
Riva, N., & Ageno, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030743 · Cited by 29 · cited 1×
“Venous thromboembolism at uncommon sites is discussed in another article of this VTE compendium [4].”
BackgroundGodinho, J. P. B., Casa-Nova, M., Moreira-Pinto, J., Simões, P., Branco, F. P., Leal-Costa, L., Faria, A., Lopes, F., Teixeira, J. A., & Passos‐Coelho, J. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0510 · Cited by 28 · cited 1×
“For pancreatic ductal adenocarcinoma, the incidence of VTE approaches 20% over the first twelve months after diagnosis, and this number may be even higher in populations with higher proportions of metastatic disease [159,160].”
BackgroundGade, I. L., Brækkan, S. K., Næss, I. A., Hansen, J.-B., Rosendaal, F. R., Cannegieter, S. C., Overvad, K., Jensvoll, H., Hammerstrøm, J., Gran, O. V., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.09.002 · Cited by 26 · cited 1×
“Patients with hematologic malignancies are also at increased risk of VTE, except for some indolent lymphoma subtypes [158].”
BackgroundHomocysteine and venous thromboembolism- Is there any link?
Hirmerová, J. (2013) · Cor et Vasa · doi:10.1016/j.crvasa.2013.01.007 · Cited by 25
New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients
MacDougall, K. N., & Spyropoulos, A. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041002 · Cited by 25 · cited 1×
“A recent publication in this VTE series explores the recent trials for extended VTE prophylaxis and suggests an algorithm to determine which patients may benefit from extended prophylaxis [135].”
BackgroundKim, K., Kang, D.-G., Khurana, S. S., Lee, S., Cho, Y.-J., & Bae, D.-K. (2013) · Knee Surgery and Related Research · doi:10.5792/ksrr.2013.25.2.43 · Cited by 21
Predictive factors for cancer-associated thrombosis in a large retrospective single-center study
Haltout, J., Awada, A. H., Paesmans, M., Moreau, M., Klastersky, J. A., Machiels, G., Ignatiadis, M., & Kotecki, N. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-018-4602-6 · Cited by 17 · cited 1×
“Elevated CRP, creatinine, and nodal involvement may also be markers of VTE risk [179].”
BackgroundTurrentine, F. E., Sohn, M., Wilson, S. L., Stanley, C., Novicoff, W. M., Sawyer, R. G., & Williams, M. D. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.01.013 · Cited by 15 · cited 2×
“Studies indicate that computer alert interventions can increase adherence to appropriate VTE risk-stratification [187], reduce costs by avoiding unnecessary thromboprophylaxis in low-risk patients [188], and decrease preventable harm from VTE [131,132,188].”
BackgroundThromboprophylaxis following cesarean section – a nation-wide survey from Germany
Goecke, T. W., Voigt, F., & Rath, W. H. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1550064 · Cited by 14
Hirsh, J., Ginsberg, J. S., Chan, N., Guyatt, G. H., & Eikelboom, J. W. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-07-0562 · Cited by 14 · cited 2×
“Recent thinking questions this assumption [32,52].”
BackgroundSelf-citationThromboembolism in children with cancer: a retrospective multicenter study in Korea
Choi, H. S., Kim, H. J., Kang, H. J., Lee, J. W., Shin, H. Y., Park, H. J., Park, B.-K., Lee, Y. H., Lee, J. A., Lim, Y. J., et al. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01808-x · Cited by 11
Improving venous thromboembolism prophylaxis through critical thinking and health informatics
Taha, H., Govindraj, E., Jaber, F., Shehadeh, G., Kelly, B., Krishnan, S., & Hamed, W. K. (2020) · BMJ Open Quality · doi:10.1136/bmjoq-2019-000885 · Cited by 8 · cited 1×
“Studies indicate that computer alert interventions can increase adherence to appropriate VTE risk-stratification [187], reduce costs by avoiding unnecessary thromboprophylaxis in low-risk patients [188], and decrease preventable harm from VTE [131,132,188].”
Background
Cited by
O’Sullivan, J. W., Raghavan, S., Marquez-Luna, C., Luzum, J. A., Damrauer, S. M., Ashley, E. A., O’Donnell, C. J., Willer, C. J., Natarajan, P., & on behalf of the American Heart Association Council on Genomic and Precision Medicine; Council on Clinical Cardiology; Council on Arteriosclerosis, T. A. V. B. C. O. C. R. A. I. C. O. L. A. C. H. A. C. O. P. V. D. (2022) · Circulation · doi:10.1161/cir.0000000000001077 · Cited by 412
Metadata
- Authors
- Nicholson, M., Chan, N., Bhagirath, V., & Ginsberg, J.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-08-01
- Volume
- 9
- Issue
- 8
- Pages
- 2467
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3046665734
- Cited by
- 224
- References
- 170
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.